Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies

Inclusion Criteria:

Phase I: Patients must have histologically confirmed relapsed or refractory Non-Hodgkin's lymphoma, Hodgkin's Disease or multiple myeloma (defined by World Health Organization (WHO) criteria).

Phase II: Patients must have histologically confirmed relapsed or refractory T-Cell Lymphoma (as defined by WHO criteria).

* Must have received first line chemotherapy. No upper limit for the number of prior therapies
* Evaluable Disease
* Age ≥18 years
* Eastern Cooperative Oncology Group (ECOG) performance status ≤2
* Patients must have adequate organ and marrow function as defined in the protocol
* Adequate Contraception
* Ability to understand and the willingness to sign a written informed consent document
* Inclusion Criteria for Multiple Myeloma patients specified in the protocol

Exclusion Criteria:

* Prior Therapy

  * Exposure to chemotherapy or radiotherapy within 2 weeks (6 weeks for nitrosureas or mitomycin C) prior to entering the study or those who have not recovered from adverse events due to agents administered more than 2 weeks earlier
  * Systemic steroids that have not been stabilized to the equivalent of ≤10 mg/day prednisone prior to the start of the study drugs
  * No other investigational agents are allowed
* Central nervous system metastases, including lymphomatous meningitis
* History of allergic reactions to Pralatrexate or Romidepsin
* Uncontrolled intercurrent illness
* Pregnant women
* Nursing women
* Current malignancy or history of a prior malignancy, as outlined in the protocol
* Patient known to be Human Immunodeficiency Virus (HIV)-positive
* Active Hepatitis A, Hepatitis B, or Hepatitis C infection